See What HealthDay Can Do For You
Contact Us

October 2010 Briefing - Ophthalmology

Here are what the editors at HealthDay consider to be the most important developments in Ophthalmology for October 2010. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.

Primary Care Trails Other Specialties in Hourly Wages

TUESDAY, Oct. 26 (HealthDay News) -- Primary care physicians have substantially lower hourly wages than other specialists, and although most physicians find Medicare reimbursement inequitable, they show little consensus on how to reform it, according to two studies published in the Oct. 25 issue of the Archives of Internal Medicine.

Abstract - Leigh
Full Text (subscription or payment may be required)
Abstract - Federman
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Eye Damage Seen in Anorexia Nervosa

FRIDAY, Oct. 22 (HealthDay News) -- Anorexia nervosa (AN) may cause serious eye damage, even without noticeable vision loss, according to research published online Oct. 19 in the British Journal of Ophthalmology.

Full Text (subscription or payment may be required)

FDA Issues Warnings About Unapproved "Chelation" Drugs

FRIDAY, Oct. 15 (HealthDay News) -- The U.S. Food and Drug Administration has notified health care professionals and consumers that no evidence has proved that nonprescription "chelation" products actually rid the body of toxic metals and can treat a variety of serious conditions and diseases.

More Information

Use of 'Poppers' Linked to Vision Loss in Several Patients

WEDNESDAY, Oct. 13 (HealthDay News) -- Alkyl nitrite "poppers" -- which have long been used as a recreational drug -- may be associated with phosphenes and prolonged vision loss, according to a letter published in the Oct. 14 issue of The New England Journal of Medicine.

Full Text

Macular Degeneration Treatments Assessed

TUESDAY, Oct. 12 (HealthDay News) -- Among patients with age-related macular degeneration, the use of bevacizumab and ranibizumab is not associated with higher risk of adverse outcomes including death, myocardial infarction, bleeding, and stroke, according to research published in the October Archives of Ophthalmology.

Full Text (subscription or payment may be required)

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.